Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later

Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later

Published

on

Revvity reports that its Signals Software business is launching Signals for Startups, a new program designed to help emerging biotech companies adopt scalable informatics capabilities earlier in their growth journey.

Built for early-stage biotechs, the program combines access to Signals software with guided onboarding and best-practice configurations for smaller biotechs to help accelerate innovation, improve scientific productivity and shorten time-to-value, according to a company spokesperson.

Startup biotechs are often under pressure to move quickly with limited IT, informatics, and operational resources while managing increasingly complex discovery data. Signals for Startups addresses this challenge with a purpose-built, scalable Signals environment that helps teams focus on science while establishing a strong digital foundation from day one, explains Kevin Willoe, president of Revvity Signals Software, adding that out-of-the-box configurations for large and small molecules enable companies to accelerate adoption, standardize data, and enhance collaboration on a proven, scalable informatics infrastructure.

“Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale,” he continues. “By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.”

Signals for Startups is expected to be available in the U.S., Europe, the Middle East, and Africa later this month.

 

The post Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

Published

on

Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”​ ​Read More

Continue Reading

Uncategorized

STAT+: Is there a pharma mega-merger in the making?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hiya, and welcome back to The Readout. 

Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hiya, and welcome back to The Readout. 

Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech

Published

on

BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will take over as CEO in early 2027.

Continue Reading
Advertisement

Trending